BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:zasocitinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of zasocitinib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07244263-101@assetmemo.bio
DTSTAMP:20261121T005329Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:zasocitinib: Phase 2 readout est. (NCT07244263)
DESCRIPTION:zasocitinib\, phase 2\, Hidradenitis Suppurativa.\nStudy: A Stu
 dy of Zasocitinib in Adults With Hidradenitis Suppurativa\nEstimated prima
 ry completion: 5 February 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/zasocitinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07244263
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06233461-101@assetmemo.bio
DTSTAMP:20261121T005329Z
DTSTART;VALUE=DATE:20270217
DTEND;VALUE=DATE:20270218
SUMMARY:zasocitinib: Phase 2 readout est. (NCT06233461)
DESCRIPTION:zasocitinib\, phase 2.\nStudy: A Study on the Safety of TAK-279
  and Whether it Can Reduce Inflammation in the Bowel of Participants With 
 Moderately to Severely Active Crohn's Disease\nEstimated primary completio
 n: 17 February 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 zasocitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06233461
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07108283-101@assetmemo.bio
DTSTAMP:20261121T005329Z
DTSTART;VALUE=DATE:20270326
DTEND;VALUE=DATE:20270327
SUMMARY:zasocitinib: Phase 2 readout est. (NCT07108283)
DESCRIPTION:zasocitinib\, phase 2\, Vitiligo.\nStudy: A Study of Zasocitini
 b in Adults With Nonsegmental Vitiligo\nEstimated primary completion: 26 M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zasocitini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 108283
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06671496-101@assetmemo.bio
DTSTAMP:20261121T005329Z
DTSTART;VALUE=DATE:20270518
DTEND;VALUE=DATE:20270519
SUMMARY:zasocitinib: Phase 3 readout est. (NCT06671496)
DESCRIPTION:zasocitinib\, phase 3\, Psoriatic Arthritis.\nStudy: A Study of
  Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been 
 Treated With Biologic Medicines\nEstimated primary completion: 18 May 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/zasocitinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06671496
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06671483-101@assetmemo.bio
DTSTAMP:20261121T005329Z
DTSTART;VALUE=DATE:20270518
DTEND;VALUE=DATE:20270519
SUMMARY:zasocitinib: Phase 3 readout est. (NCT06671483)
DESCRIPTION:zasocitinib\, phase 3\, Psoriatic Arthritis.\nStudy: A Study of
  Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologi
 c Medicines\nEstimated primary completion: 18 May 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/zasocitinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06671483
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07752108-101@assetmemo.bio
DTSTAMP:20261121T005329Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:zasocitinib: Phase 3 readout est. (NCT07752108)
DESCRIPTION:zasocitinib\, phase 3\, Psoriasis.\nStudy: A Study of Zasocitin
 ib in Adults With Non-pustular Palmoplantar Psoriasis\nEstimated primary c
 ompletion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/zasocitinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07752108
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07403968-101@assetmemo.bio
DTSTAMP:20261121T005329Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:zasocitinib: Phase 2 readout est. (NCT07403968)
DESCRIPTION:zasocitinib\, phase 2.\nStudy: A Study of Zasocitinib (TAK-279)
  in Adults With Active Crohn's Disease\nEstimated primary completion: 30 M
 arch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zasocitini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 403968
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06550076-101@assetmemo.bio
DTSTAMP:20261121T005329Z
DTSTART;VALUE=DATE:20290805
DTEND;VALUE=DATE:20290806
SUMMARY:zasocitinib: Phase 3 readout est. (NCT06550076)
DESCRIPTION:zasocitinib\, phase 3\, Psoriasis.\nStudy: A Study of TAK-279 i
 n Participants With Moderate-to-Severe Plaque Psoriasis\nEstimated primary
  completion: 5 August 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/zasocitinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06550076
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286058-101@assetmemo.bio
DTSTAMP:20261121T005329Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:zasocitinib: Phase 3 readout est. (NCT07286058)
DESCRIPTION:zasocitinib\, phase 3\, Psoriatic Arthritis.\nStudy: Continuati
 on Study of Zasocitinib in Adults With Psoriatic Arthritis\nEstimated prim
 ary completion: 18 December 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/zasocitinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07286058
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764615-101@assetmemo.bio
DTSTAMP:20261121T005329Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:zasocitinib: Phase 2 readout est. (NCT06764615)
DESCRIPTION:zasocitinib\, phase 2.\nStudy: A Continuation Study of TAK-279 
 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)\nEstimated
  primary completion: 30 December 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/zasocitinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06764615
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871721-101@assetmemo.bio
DTSTAMP:20261121T005329Z
DTSTART;VALUE=DATE:20300418
DTEND;VALUE=DATE:20300419
SUMMARY:zasocitinib: Phase 3 readout est. (NCT07871721)
DESCRIPTION:zasocitinib\, phase 3\, Psoriatic Arthritis.\nStudy: A Study of
  Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)\nEstim
 ated primary completion: 18 April 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/zasocitinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07871721
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07250802-101@assetmemo.bio
DTSTAMP:20261121T005329Z
DTSTART;VALUE=DATE:20340703
DTEND;VALUE=DATE:20340704
SUMMARY:zasocitinib: Phase 3 readout est. (NCT07250802)
DESCRIPTION:zasocitinib\, phase 3\, Psoriasis.\nStudy: A Long-Term Study of
  Zasocitinib in Children and Teenagers With Plaque Psoriasis\nEstimated pr
 imary completion: 3 July 2034. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/zasocitinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07250802
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
